Zosuquidar (LY335979) 3HCl: P-gp Inhibitor for Chemotherapy Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent, selective P-glycoprotein (P-gp) inhibitor that reverses multidrug resistance (MDR) in cancer by competitively blocking P-gp-mediated drug efflux at low micromolar concentrations (https://doi.org/10.1016/j.biopha.2025.118665). It restores the efficacy of chemotherapeutics such as vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp overexpressing cell lines (https://www.apexbt.com/zosuquidar.html). In murine models, zosuquidar enhances antitumor activity and prolongs survival without altering pharmacokinetics (https://biotin-hpdp.com/index.php?g=Wap&m=Article&a=detail&id=15921). Clinical studies indicate effective P-gp inhibition with minimal toxicity in combination chemotherapy regimens (https://doi.org/10.1016/j.biopha.2025.118665). Zosuquidar is supplied by APExBIO as SKU A3956 and is soluble in DMSO, with recommended storage at -20°C.

Biological Rationale

P-glycoprotein (P-gp, encoded by ABCB1) is an ATP-dependent efflux transporter expressed in tissues such as the brain, liver, kidney, and intestinal epithelium, as well as in various tumor cell populations. P-gp actively exports a diverse range of xenobiotic compounds, including many chemotherapeutic agents, out of cells, thereby reducing intracellular drug accumulation and efficacy (https://doi.org/10.1016/j.biopha.2025.118665). Overexpression of P-gp is a well-characterized mechanism underlying multidrug resistance (MDR) in cancer, particularly in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and solid tumors. Pharmacological inhibition of P-gp has been shown to restore sensitivity to cytotoxic agents in preclinical and clinical studies (https://biotin-hpdp.com/index.php?g=Wap&m=Article&a=detail&id=15919). Disrupting P-gp function represents a rational strategy for overcoming MDR and improving chemotherapy outcomes.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a third-generation, highly selective P-gp inhibitor. Its molecular structure enables competitive inhibition at the substrate binding site, specifically blocking the efflux of chemotherapeutic drugs like vinblastine and doxorubicin (https://www.apexbt.com/zosuquidar.html). Zosuquidar does not significantly inhibit other ABC transporters (e.g., MRP1/ABCC1, BCRP/ABCG2), minimizing off-target effects. In vitro, zosuquidar acts at concentrations as low as 0.1–1 μM, restoring drug accumulation in resistant cell lines. The compound’s high affinity for P-gp and lack of major effect on cytochrome P450 enzymes reduce the risk of pharmacokinetic drug-drug interactions (https://doi.org/10.1016/j.biopha.2025.118665). Its selectivity profile has been validated using Caco-2 and transfected HEK293 cell models.

Evidence & Benchmarks

• Zosuquidar at 1 μM restores vinblastine accumulation in P-gp overexpressing leukemia cell lines to levels observed in non-resistant controls (https://doi.org/10.1016/j.biopha.2025.118665).
• Murine models of MDR leukemia treated with zosuquidar plus chemotherapy show a significant increase in survival time versus chemotherapy alone (https://biotin-hpdp.com/index.php?g=Wap&m=Article&a=detail&id=15921).
• In clinical phase I/II trials, zosuquidar in combination with CHOP chemotherapy demonstrated effective P-gp inhibition and no dose-limiting toxicity (https://doi.org/10.1016/j.biopha.2025.118665).
• Pharmacokinetic studies confirm zosuquidar does not significantly alter plasma levels of co-administered chemotherapeutics in animal and human studies (https://cct241533hydrochloride.com/index.php?g=Wap&m=Article&a=detail&id=14394).
• In vitro, zosuquidar shows minimal interaction with cytochrome P450 enzymes, supporting its use in multi-agent chemotherapy regimens (https://doi.org/10.1016/j.biopha.2025.118665).

Compared to earlier reviews such as "Zosuquidar (LY335979) 3HCl: Precision Reversal of Multidrug Resistance", which focus on mechanistic insights, this article provides updated clinical benchmarks and workflow integration tips for translational research. For a systems-level perspective on MDR reversal, see "Zosuquidar (LY335979) 3HCl: Novel Paradigms in Reversing MDR"—here, we emphasize practical assay and storage parameters in addition to molecular selectivity.

Applications, Limits & Misconceptions

Zosuquidar is validated for use in MDR reversal studies in hematologic malignancies (e.g., AML) and solid tumors with documented P-gp overexpression. It is effective in both in vitro cell assays and in vivo xenograft models. Common applications include restoration of chemotherapy sensitivity, pharmacokinetic modulation studies, and transporter selectivity profiling (https://www.apexbt.com/zosuquidar.html).

Common Pitfalls or Misconceptions

• Zosuquidar is not a general ABC transporter inhibitor: It does not block MRP1 or BCRP, which can mediate MDR independently of P-gp (https://doi.org/10.1016/j.biopha.2025.118665).
• Not effective if MDR is not P-gp-mediated: Tumors using alternative resistance mechanisms will not respond to zosuquidar (https://biotin-hpdp.com/index.php?g=Wap&m=Article&a=detail&id=15919).
• Does not reverse resistance to non-P-gp substrates: Drugs not exported by P-gp will not show restored efficacy with zosuquidar.
• Long-term solution storage not recommended: Zosuquidar is stable in DMSO at -20°C, but extended solution storage can reduce activity (https://www.apexbt.com/zosuquidar.html).
• Clinical benefit is context-dependent: Efficacy in patients depends on tumor P-gp expression and multidrug regimens.

For troubleshooting and advanced usage protocols, refer to "Maximizing Chemotherapy Sensitization: Practical Solutions for MDR Assays", which offers scenario-driven guidance distinct from this mechanistic overview.

Workflow Integration & Parameters

• Solubility: Zosuquidar (LY335979) 3HCl is soluble in DMSO up to 50 mM; dilute in aqueous buffer immediately before use.
• Storage: Store lyophilized zosuquidar at -20°C; avoid repeated freeze-thaw cycles.
• Recommended concentration for in vitro assays: 0.1–1 μM for P-gp inhibition; titrate for specific cell lines.
• Pharmacokinetics: Zosuquidar does not significantly alter the plasma pharmacokinetics of co-administered chemotherapeutics (https://doi.org/10.1016/j.biopha.2025.118665).
• Assay controls: Include P-gp-negative cell lines to confirm selectivity.

APExBIO provides zosuquidar (SKU A3956) with detailed handling instructions. For protocol optimization, see the Zosuquidar (LY335979) 3HCl product page.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a robust tool for MDR reversal in cancer research, offering high selectivity for P-gp with minimal toxicity and pharmacokinetic interference. Its role in restoring chemotherapy efficacy is supported by preclinical and clinical benchmarks. Ongoing research is clarifying its optimal integration with multi-agent regimens and MDR biomarker stratification. For future directions in MDR targeting and transporter pharmacology, consult recent translational studies and workflow guides.